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C esarean delivery is the most common surgical proced­ure worldwide, performed to expedite delivery and avoid neonatal complications. Fetal surveillance is rou­
tinely offered to patients in labour to reduce the risk of adverse 
neonatal outcomes, as well as the risk of unnecessary emer­
gency cesarean deliveries and other maternal interventions. 
Fetal surveillance aims to detect intrapartum hypoxia from 
acute or subacute adverse events in labour requiring medical 
intervention and to reduce the risk of serious complications 
such as neonatal cerebral palsy, hypoxic–ischemic encephalop­
athy or stillbirth.
Monitoring the fetal heart rate to detect intrapartum hypoxia 
using simple surveillance techniques, such as the Pinard 
stethoscope, has been practised for decades.1 Over the last 
50 years, several newer surveillance methods have been evalu­
ated, with varied uptake in practice.2 Cardiotocography (CTG) 
remains the most common surveillance method used in high­risk 
pregnancies.3 However, given its limited accuracy, many research­
ers have evaluated its use in combination with other surveillance 
methods, such as fetal heart electrocardiogram (STAN), fetal scalp 
pH analysis (FBS) or fetal pulse oximetry (FPO), and with com­
puter­aided decision models (cCTG) to improve its diagnostic 
value.4–6 Despite extensive investment in clinical research, the 
overall effectiveness of such methods in improving maternal and 
neonatal outcomes remains debatable as stillbirth rates have pla­
teaued worldwide, while cesarean delivery rates continue to rise.7,8
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ABSTRACT
BACKGROUND: Cesarean delivery is the 
most common surgical procedure 
worldwide. Intrapartum fetal surveil­
lance is routinely offered to improve 
neonatal outcomes, but the effects 
of different methods on the risk of 
emergency cesarean deliveries remains 
uncertain. We conducted a systematic 
review and network meta­analysis to 
evaluate the effectiveness of different 
types of fetal surveillance.
METHODS:  We searched MEDLINE, 
Embase and CENTRAL until June 1, 2020, 
for randomized trials evaluating any 
intrapartum fetal surveillance method. 
We performed a network meta­analysis 
within a frequentist framework. We 
assessed the quality and network incon­
sistency of trials. We reported primarily 
on intrapartum emergency cesarean 
deliveries and other secondary maternal 
and neonatal outcomes using risk ratios 
(RRs) and 95% confidence intervals (CIs).
RESULTS: We included 33 trials (118 863 
patients) evaluating intermittent auscul­
tation with Pinard stethoscope/hand­
held Doppler (IA), cardiotocography 
(CTG), computerized cardiotocography 
(cCTG), CTG with fetal scalp lactate 
(CTG­lactate), CTG with fetal scalp pH 
analysis (CTG­FBS), CTG with fetal pulse 
oximetry (FPO­CTG), CTG with fetal 
heart electrocardiogram (CTG­STAN) 
and their combinations. Intermittent 
auscultation reduced the risk of emer­
gency cesarean deliveries compared 
with other types of surveillance (IA v. 
CTG: RR 0.83, 95% CI 0.72–0.97; IA v. 
CTG­FBS: RR 0.71, 95% CI 0.63–0.80; IA 
v.CTG­lactate: RR 0.77, 95% CI 0.64–0.92; 
IA v. FPO­CTG: RR 0.75, 95% CI 0.65–0.87; 
IA v.FPO­CTG­FBS: RR 0.81, 95% CI 0.67–
0.99; cCTG­FBS v. IA: RR 1.21, 95% CI 
1.04–1.42), except STAN­CTG­FBS 
(RR 1.17, 95% CI 0.98–1.40). There was a 
similar reduction observed for emer­
gency cesarean deliveries for fetal dis­
tress. None of the evaluated methods 
was associated with a reduced risk of 
neonatal acidemia, neonatal unit admis­
sions, Apgar scores or perinatal death.
INTERPRETATION: Compared with other 
types of fetal surveillance, intermittent 
auscultation seems to reduce emer­
gency cesarean deliveries in labour 
without increasing adverse neonatal 
and maternal outcomes.
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Existing meta­analyses evaluating different intrapartum fetal 
surveillance methods remain limited to head­to­head compari­
sons of monitoring techniques, without a comprehensive assess­
ment of their effectiveness in improving maternal and neonatal 
pregnancy outcomes.4,9–13 We conducted a systematic review of 
randomized trials and a network meta­analysis to evaluate the 
effectiveness of all available fetal surveillance methods in 
improving maternal and neonatal outcomes.
Methods
Search strategy
We conducted our systematic review according to a prospec­
tively registered protocol (CRD42018118082) and reported the 
findings as per established guidelines.14 We searched MEDLINE, 
Embase and Cochrane CENTRAL from database inception to 
June 1, 2020, for randomized trials evaluating any fetal surveil­
lance method in labour. We developed our search strategy by 
consulting relevant Medical Subject Headings (MeSH) and com­
bining key search words using Boolean operators within the NICE 
Healthcare Databases Advanced Search platform (hdas.nice.org.
uk) (Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/
cmaj.202538/tab­related­content). We also conducted supple­
mentary searches in Google Scholar and Scopus to identify any 
missing evidence. No search filters or language limitations were 
employed; articles in non­English languages were obtained and 
translated if deemed relevant. We manually screened the bibliog­
raphies of potentially relevant articles and published systematic 
reviews on the topic to identify any additional relevant trials. We 
contacted the authors of included trials seeking further informa­
tion as necessary. We did not include any unpublished data in 
the analysis. We consulted the James Lind Library and previous 
Cochrane reviews to identify the primary outcome and other out­
comes of interest to stakeholders. We did not involve patients in 
the design of our research study. 
Selection of studies and outcome reporting
Two reviewers (E.M. and S.B.) independently selected and per­
formed data extraction, which was further checked by a third 
reviewer (B.H.A.). Inconsistencies and disagreements were 
resolved by discussion and consensus with a fourth reviewer 
(S.T.). We included all randomized controlled trials that evalu­
ated the effectiveness of existing fetal surveillance methods in 
labour. We included studies with multiple comparison arms, 
those evaluating a combination of surveillance types (e.g., fetal 
electrocardiogram and cardiotocography) and studies involving 
both high­ and low­risk pregnancies. We combined instruments 
used for the same surveillance type under the same comparison 
arm (e.g., Pinard stethoscope and hand­held Doppler combined 
as intermittent auscultation). We excluded studies that included 
only preterm pregnancies and those comparing different instru­
ments for the same surveillance type (e.g., Pinard stethoscope v. 
hand­held Doppler for intermittent auscultation). We also 
excluded studies that did not report on any of the outcomes we 
set a priori in our protocol (e.g., studies reporting only on the 
number of fetal blood sampling attempts).
Our main outcome was the incidence of emergency cesar­
ean deliveries in labour. We also reported on other maternal 
outcomes such as emergency cesarean delivery in labour spe­
cifically for suspected fetal distress, instrumental deliveries and 
instrumental deliveries specifically for suspected fetal distress. 
Neonatal outcomes included neonatal acidemia (diagnosed 
using umbilical cord blood gases, as defined by the study 
authors), admissions to the neonatal intensive care unit, neo­
natal Apgar scores < 7 at the 5th minute and perinatal death 
(i.e., any fetal death beyond 24 weeks’ gestation, plus any neo­
natal death within the first week of life). We extracted data on 
the country of the study, the publication journal, trial settings, 
population characteristics, the evaluated fetal surveillance 
types, the criteria used to interpret the surveillance findings, 
the action algorithm used in the trial setting for acting on wor­
rying fetal signs and the definition of fetal acidemia used by the 
trial investigators.
Quality assessment
Two reviewers (E.H. and S.B.) independently assessed the 
quality of included studies using the Cochrane risk of bias 
assessment tool.15 Each study was assessed for the quality of 
randomization and sequence generation, assignment conceal­
ment, outcome assessment, completeness of outcome data 
and selective outcome reporting. Blinding was deemed non­
feasible because of the nature of the evaluated interventions 
and was excluded from the quality assessment. Efforts to stan­
dardize the management of patients with suspected fetal dis­
tress were taken into account when evaluating detection and 
outcome assessment bias. Similarly, trials that employed a 
quality assurance process to ensure adequate diagnosis of 
fetal compromise against their study protocol were deemed to 
have less risk of outcome assessment bias compared with 
those that did not employ any quality measures or report on 
protocol violations.
Statistical analysis
We performed a network meta­analysis within a frequentist 
framework. We fit multivariate meta­analysis models with ran­
dom effects using the network package in Stata,16,17 exploiting 
the direct and indirect randomized evidence to determine the 
relative effects and ranking. We reported the effects of the inter­
ventions using risk ratios (RRs) with 95% confidence intervals 
(CIs). For the primary analysis on all emergency cesarean deliver­
ies, we only included fetal surveillance types that were evaluated 
in more than 1 randomized trial, decided a priori to minimize the 
risk of inconsistency in the network. We also conducted a sensi­
tivity analysis with all eligible trials reporting on the primary out­
come, including those evaluated in only 1 trial. We calculated the 
mean rank and the surface under the cumulative ranking curve 
(SUCRA) for each intervention for all reported outcomes. Surveil­
lance methods with a SUCRA value close to 100% had the highest 
cumulative rank (i.e., lowest likelihood) of achieving the adverse 
maternal or neonatal outcome.18,19
We used the design­by­treatment interaction model to check 
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common estimate for the heterogeneity variance across the dif­
ferent comparisons in the network.20 We investigated and 
detected inconsistency by comparing the direct and indirect evi­
dence within the network using the node­splitting approach,21 
assuming a common heterogeneity estimate within each loop 
(i.e., when numerous trials compare a minimum of 3 treatments 
to one another).22 We also investigated potential sources of 
inconsistency within relevant trials. In cases where inconsistency 
was detected, we conducted a network meta­regression com­
pared with reference treatment (cardiotocography with fetal 
scalp blood pH sampling), testing for 2 potential effect modifiers, 
gestational age (preterm v. term) and pregnancy risk status (high 
risk v. low risk).23 All analyses were conducted using Stata statis­
tical software, release 14 (StataCorp).16,19,24 
Results
Of 351 potentially relevant citations, we included 33 random­
ized trials (n = 120 151 patients) in our systematic review 
(Figure 1, Table 1). Most included trials were from high­income 
countries (United States, n = 6;26,27,32–34,38 United Kingdom, 
n  =  5;28,37,40,44,54 Australia, n = 4;30,31,47,57 Sweden, n = 4),25,35,55,56 
except for 2 studies (Tanzania and India).41,42 The median sam­
ple size was 894 patients (range 100–47 062). Fifteen trials 
(45%)25–27,31,32,36,39,41,43–46,49,51,53 included patients at 36 weeks’ ges­
tation or more, and the remaining included patients at 
26–42  weeks’ gestation.28–30,33–35,38,40,50,52,54,56 Two­thirds of trials 
( 7 3 % )  i n c l u d e d  p a t i e n t s  w i t h  h i g h ­ r i s k  p r e g n a n ­
cies,25–34,36,38,39,41,44,47,48,50,51,53,54 3 (9%) included patients with low­
risk pregnancies35,37,57 and 4 (12%) included pregnancies of any 
risk.40,42,43,52 Three studies did not report on pregnancy 
risks.45,46,49 The inclusion and exclusion criteria of each trial are 
summarized in Appendix 1, Supplementary Table 1. 
Overall, we evaluated 10 fetal surveillance types, including 
intermittent auscultation (IA), cardiotocography (CTG) alone or 
in combination with computer­aided cardiotocography (cCTG), 
fetal scalp blood lactate sampling (CTG­lactate), fetal scalp 
blood pH sampling (CTG­FBS), fetal pulse oximetry (FPO­CTG), 
fetal heart electrocardiogram (STAN­CTG) and other combina­
tions (STAN­CTG­FBS, FPO­CTG­FBS, cCTG­FBS).
All trials conducted head­to­head comparisons of 2 fetal 
surveillance methods with the exception of 1 trial that used a 
3­arm design.34 Two methods, cCTG and STAN­CTG, were 
evalu ated in only a single trial.26,36 These methods were there­
fore excluded from the primary analysis and were investigated 
in sensitivity analyses. Twenty­eight trials reported on all 
emergency cesarean deliveries in labour and 23 reported on 
cesarean deliveries for suspected fetal distress. Appendix 1, 
Supplementary Table 3 summarizes the number of trials and 
participants contributing to each reported outcome per sur­
veillance method. Appendix 1, Supplementary Table 4 sum­
marizes the criteria that each trial used to interpret the find­
ings of the fetal surveillance methods that it compared, as well 
as each trial’s management algorithms and definitions of neo­
natal acidemia.
Quality of the included studies
The overall quality of included trials was moderate (Appendix 1, 
Supplementary Figure 1 and Supplementary Table 7). Trials that 
were conducted before the year 2000 showed high risk of bias in 
most of the evaluated domains. Ten trials (30%) showed high risk 
of bias for randomization and 11 (33%) for assignment conceal­
ment. Six trials showed high risk of bias for each of outcome 
assessment31,34,39,41,47, 57 and selective reporting (18%).31,33,39,41,47,57 
Only 2 trials (6%) had high loss to follow­up and data incom­
pleteness.41,57 Overall, two­thirds of the included trials showed 
low risk of bias across the 5 evaluated elements.
Emergency cesarean deliveries in labour
Figure 2 illustrates the network of trials reporting on all emer­
gency cesarean deliveries in labour (28 trials, including 
103 676 patients). Overall, IA reduced the risk of cesarean deliver­
ies in labour compared with other methods (IA v. CTG: RR 0.83, 
95% CI 0.72–0.97; IA v. CTG­FBS: RR 0.71, 95% CI 0.63–0.80; IA v. 
CTG­lactate: RR 0.77, 95% CI 0.64–0.92; IA v. FPO­CTG: RR 0.75, 
95% CI 0.65–0.87; IA v. FPO­CTG­FBS: RR 0.81, 95% CI 0.67–0.99; 
cCTG­FBS v. IA: RR 1.21, 95% CI 1.04–1.42) except when com­
pared with STAN (STAN­CTG­FBS v. IA: RR 1.17, 95% CI 0.98–1.40) 
(Figure  3A). Intermittent auscultation was also most likely to 
reduce emergency cesarean deliveries (SUCRA 98.6), followed by 
STAN­CTG­FBS (SUCRA 72.3); CTG­FBS had the lowest likelihood 
of reducing the risk of emergency cesarean delivery (SUCRA 7.6) 
(Table 2, Figure 4). Using only CTG showed a similar effect on all 
emergency cesarean deliveries in labour compared with when it 
was combined with FBS (RR 1.17, 95% CI 0.99–1.40), STAN and 
FBS (RR 0.97, 95% CI 0.89–1.07) or with FPO (RR 1.02, 95% CI 
0.91–1.16) (Appendix 1, Supplementary Figure 2). We detected 
Total citations from electronic searches
n = 351  
Full articles assessed for eligibility 
n = 44
Included studies
n = 351 (120 151 patients)  
Excluded citations aer title 
and abstract screening  n =  307





Comparing variations of the same method  n = 4
Evaluating antenatal interventions  n = 5
Not reporting relevant outcomes  n = 5
Not randomized studies  n = 4        
Additional studies from
bibliographies  n = 7 
Figure 1: Flow chart of the study selection and inclusion process for net­
work meta­analysis on intrapartum fetal surveillance.
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Amer­Wahlin et al., 200125 Sweden 3 labour wards 4966 STAN­CTG­FBS CTG­FBS > 36
Belfort et al., 201526 US 16 university maternity units 11 108 STAN­CTG CTG > 36
Bloom et al.,  200627 US 14 university maternity units 5341 CTG­FPO CTG ≥ 36
Brocklehurst et al., 201728 UK 24 maternity units 47 062 cCTG­FBS CTG­FBS ≥ 35
Caliskan et al., 200929 Turkey Tertiary referral centre 230 CTG­FPO CTG ≥ 34
East et al., 200630 Australia 4 maternity hospitals 601 FPO­CTG­FBS CTG­FBS ≥ 26
East et al., 201631 Australia Tertiary referral centre 123 CTG­lactate CTG Full term
Garite et al., 200032 US 9 maternity hospitals 1010 FPO­CTG­FBS CTG­FBS ≥ 36
Haverkamp et al., 197633 US NR 483 CTG IA ≥ 35
Haverkamp et al., 197934 US General hospital 690 CTG CTG­FBS > 34
Haverkamp et al., 197934 US General hospital 690 CTG IA > 34
Herbst et al., 199435 Sweden Tertiary referral centre 4044 IA CTG­FBS > 33
Ignatov et al., 201636 Bulgaria Tertiary referral centre 720 cCTG CTG­FBS ≥ 37
Kelso et al., 197837 UK Tertiary referral centre 504 CTG IA NR
Klauser et al., 200538 US Hospital for women & infants 360 CTG­FPO CTG ≥ 28
Kuhnert et al., 200439 Germany Women’s hospitals. (The German 
Multicenter Study Group)
146 CTG­FBS­FPO CTG­FBS ≥ 36
Macdonald et al., 198540 UK Maternity hospital 12 964 CTG­FBS IA ≥ 28
Madaan et al., 200641 India University hospital 100 CTG IA ≥ 37
Mdoe et al., 201842 Tanzania Referral hospital 2652 CTG IA NR
Neldam et al., 198643 Denmark Labour ward in tertiary 
university hospital
1061 CTG­FBS IA ≥ 36
Nunes et al., 201744 UK 5 hospitals, 3 tertiary care units 
and 2 district general hospitals
7730 cCTG­FBS CTG­FBS ≥ 36
Ojala et al., 200645 Finland Labour ward in tertiary 
university hospital
1483 STAN­CTG­FBS CTG­FBS ≥ 36
Puertas et al., 201846 Spain University hospital 237 STAN­CTG­FBS CTG­FBS 291–294 d 
gestation
Renou et al., 197647 Australia Fetal intensive care unit 440 CTG­FBS IA NR
Strachan et al., 200048 UK, Hong Kong, 
Netherlands, 
Singapore
5 teaching hospitals 1038 STAN­CTG­FBS CTG­FBS NR
Valverde et al., 201149 Spain University hospital 180 STAN­CTG­FBS FPO­CTG­FBS Full term
van Wijngaarden et al., 199650 UK, Hong Kong 3 teaching hospitals 214 STAN­CTG­FBS CTG­FBS > 27
Vayssiere et al., 200751 France 2 maternity wards 799 STAN­CTG­FBS CTG­FBS ≥ 36
Vintzileos et al.,  199352 Greece 2 university hospitals 1428 CTG IA ≥ 26
Westerhuis et al., 201053 Netherlands 3 academic and 6 nonacademic 
teaching hospitals
5681 STAN­CTG­FBS CTG­FBS > 36
Westgate et al. 199354 UK Distric general hospital 2434 STAN­CTG­FBS CTG­FBS > 34
Westgren et al. 199855 Sweden University hospital 341 CTG­lactate CTG­FBS NR
Wiberg­Itzel et al. 200856 Sweden 10 labour ward departments 2992 CTG­lactate CTG­FBS ≥ 34
Wood et al. 198157 Australia Maternity hospital and medical 
centre
989 CTG­FBS IA NR
Note: cCTG = computer­aided cardiotocography, cCTG­FBS = computer­aided cardiotocography with fetal scalp blood pH sampling, CTG = cardiotocography,  
CTG­FBS = cardiotocography with fetal scalp blood pH sampling, CTG­lactate = cardiotocography with fetal scalp blood lactate, FPO­CTG = cardiotocography with fetal pulse oximetry, 
FPO­CTG­FBS = cardiotocography with fetal pulse oximetry and fetal blood pH sampling, IA = intermittent auscultation, NR = not reported, STAN­CTG = cardiotocograpy with fetal heart 
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significant inconsistency in this network (p = 0.01) that derived 
from evidence in the loop formed by CTG­FBS, FPO­CTG­FBS and 
STAN­CTG­FBS (Appendix 1, Supplementary Table 5). 
Twenty­three trials reported on cesarean deliveries for 
suspected fetal distress (n = 100 500) (Appendix 1, Supple­
mentary Table 3). Intermittent auscultation showed a similar 
effect in reducing cesarean deliveries compared with 
CTG  (RR 0.57,  95% CI  0.38–0.86),  CTG­FBS (RR 0.34, 
95%  CI  0.22–0.50), FPO­CTG (RR 0.42, 95% CI 0.25–0.70) and 
cCTG­FBS (RR 1.80, 95% CI 1.06–3.07) (Figure 3B). Combining 
FPO or STAN with CTG­FBS seemed to reduce the risk of 
cesarean deliveries for suspected fetal distress compared 
with using CTG­FBS alone (FPO­CTG­FBS v. CTG­FBS: RR 0.40, 
95% CI 0.21–0.77; STAN­CTG­FBS v. CTG­FBS: RR 0.47, 
95% CI 0.26–0.84), though there was no significant difference 
between the 2 combinations when compared to one another 
(STAN­CTG­FBS v. FPO­CTG­FBS: RR 1.16, 95% CI  0.77–1.74) 
(Appendix 1, Supplementary Figure 3). There was significant 
inconsistency in this network (p = 0.004) that involved evi­
dence loops for CTG­FBS, FPO­CTG­FBS and STAN­CTG­FBS 
(Appendix 1, Supplementary Table 5).
We further investigated the inconsistencies in the 12 trials 
that contributed to the evidence loop comparing CTG­FBS, 
FPO­CTG­FBS and STAN­CTG­FBS. Three trials compared FPO­
CTG­FBS to CTG­FBS, 8 trials compared STAN­CTG­FBS to CTG­
FBS and 1 trial compared STAN­CTG­FBS to FPO­CTG­FBS. All 
12 trials were conducted in tertiary maternity units in high­
income countries with similar study population characteristics. 
Two trials included patients with preterm pregnancies (CTG­
FBS­FPO v. CTG­FBS30 and CTG­FBS­STAN v. CTG­FBS50); the 
others included patients at more than 36 weeks’ gestation. 
Only 1 trial (CTG­FBS­FPO v. CTG­FBS39) showed an overall high 
risk of bias, with all remaining trials showing low to medium 
risk of bias. All trials followed established guidelines to inter­
pret the findings of STAN and FPO in their action algorithms 
(Appendix 1, Supplementary Table 4).
We conducted a metaregression to investigate the potential 
effect of pregnancy status (high v. low risk) and gestational age 
(term v. preterm) on the risk for emergency cesarean deliveries 
and for cesarean deliveries for suspected fetal distress. Results 
suggested that pregnancy status had a significant effect among 
trials comparing FPO­CTG­FBS with CTG­FBS (Appendix 1, Sup­
plementary Table 6). We conducted a sensitivity analysis, exclud­
ing trials evaluating FPO­CTG­FBS, which resolved the inconsis­
tency in both networks without any major change in the effect 
sizes among remaining comparison arms (Appendix 1, Supple­
mentary Figure 4).
Secondary outcomes
Using IA reduced the risk of all instrumental deliveries compared 
with using CTG alone (IA v. CTG: RR 0.82, 95% CI 0.73–0.93), but it 
did not show a significant difference compared with other fetal 
surveillance methods (Appendix 1, Supplementary Figure 5). In 
contrast, IA significantly reduced the risk of instrumental deliver­
ies for suspected fetal distress compared with all other fetal sur­
veillance methods (IA v. CTG: RR 0.41, 95% CI 0.30–0.57; IA v. 
CTG­FBS: RR 0.42, 95% CI 0.25–0.69; IA v. FPO­CTG­FBS: RR 0.50, 
95% CI 0.32–0.79; STAN­CTG­FBS v. IA: RR 2.14, 95% CI 1.49–3.08; 
cCTG­FBS v. IA: RR 2.52, 95%CI 1.77–3.60) (Appendix 1, Supple­
mentary Figure 6).
All types of fetal surveillance had a similar effect on the evalu­
ated neonatal outcomes (neonatal acidemia, admission to neo­
natal unit, Apgar < 7 at 5th minute and perinatal death) (Appen­
dix 1, Supplementary Figure 7–10). Table 2 shows the ranking of 
all evaluated types of surveillance according to their likelihood of 
reducing adverse neonatal outcomes. Combining FPO or STAN 
with CTG­FBS seemed to improve the likelihood of reducing 
adverse neonatal outcomes, but this did not result in a signifi­
cant difference in our network meta­analysis. We did not detect 
significant inconsistency in the evidence networks for any of the 
secondary outcomes.
Sensitivity analysis 
Our network meta­analysis that included the 2 trials evaluating 
the use of STAN­CTG and cCTG alone on emergency cesarean 
deliveries showed that the use of STAN­CTG had a similar effect 
on the risk of all emergency cesarean deliveries compared with 
other surveillance methods except STAN­CTG­FBS (RR 0.79, 
95% CI 0.64–0.98) and IA (RR 1.47, 95% CI 1.28–1.70) (Appendix 1, 
Supplementary Figures 11 and 12). A similar effect was seen for 










Figure 2: Network comparing the effectiveness of types of intrapartum 
fetal surveillance to reduce all emergency cesarean sections in labour. 
The dot size represents the number of participants in each comparison 
arm and the thickness of the lines represent the number of random­
ized trials directly comparing the pair of methods. Note: cCTG­FBS = 
computer­aided cardiotocography with fetal scalp blood pH sampling, 
CTG = cardiotocography, CTG­FBS = cardiotocography with fetal 
scalp blood pH sampling, CTG­lactate = cardiotocography with fetal scalp 
blood lactate, FPO­CTG = cardiotocography with fetal pulse oximetry, 
FPO­CTG­FBS = cardiotocography with fetal pulse oximetry and fetal 
blood pH sampling, IA = intermittent auscultation, STAN­CTG­FBS = 
cardiotocography with fetal heart electrocardiogram and fetal scalp 
blood pH sampling.
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Network meta­analysis on the use of cCTG alone suggested 
a consistent reduction in the relative risk for all emergency 
cesarean deliveries by around 50% compared with all other 
surveillance methods (Appendix 1, Supplementary Figure 11). 
No data were available on the effect of cCTG on cesarean deliv­
eries for suspected fetal distress. Given the potential high risk 
of bias and inconsistency between the indirect and the direct 
evidence sought from this small trial, we interpret these find­
ings with caution.
Interpretation
Despite the large investment in developing intrapartum fetal sur­
veillance technology over the last 5 decades, our network meta­
analysis suggests that none of the newer surveillance methods 
seem to significantly reduce emergency cesarean deliveries in 
labour or neonatal morbidity compared with using simple IA of 
the fetal heart. Combining newer methods such as STAN and FPO 
with CTG may improve its performance, thus reducing 
0.0
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Comparison RR (95% CI)
Figure 3: Network meta­analysis comparing the effectiveness of intermittent auscultation (IA) to reduce (A) all emergency cesarean deliveries in labour 
and (B) emergency cesarean deliveries for suspected fetal distress. The forest plots depict the effectiveness of IA compared with other types of fetal sur­
veillance using both mixed evidence network meta­analysis (M) and direct evidence pairwise meta­analysis (D). Note: cCTG­FBS = computer­aided car­
diotocography with fetal scalp blood pH sampling, CTG = cardiotocography, CTG­FBS = cardiotocography with fetal scalp blood pH sampling, CTG­ 
lactate = cardiotocography with fetal scalp blood lactate, FPO­CTG = cardiotocography with fetal pulse oximetry, FPO­CTG­FBS = cardiotocography 
with fetal pulse oximetry and fetal blood pH sampling, LCL = lower confidence limit, RR = risk ratio, STAN­CTG­FBS = cardiotocography with fetal heart 
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unnecessary cesarean deliveries. However, none of these combi­
nations were shown to significantly outperform IA in reducing 
adverse maternal and neonatal outcomes. Although there were 
variations in the quality and reporting across trials, leading to 
inconsistency in the evidence networks on cesarean delivery out­
comes, the effect estimates favouring IA across all evaluated 
types of surveillance were consistent in our sensitivity analyses, 
thereby increasing the generalizability of our findings. Trials 
evaluating the use of FPO contributed to statistical inconsistency 
when evaluating the incidence of emergency cesarean deliveries. 
As such, the direct and indirect evidence on the effect of FPO 
should be interpreted with caution, pending larger trials to bet­
ter evaluate its effectiveness.
Our review provides a uniquely comprehensive evidence syn­
thesis on all current types of fetal surveillance for intrapartum 
care. We leveraged both direct and indirect evidence from ran­
domized trials using the network meta­analysis methodology to 
compare and rank types of surveillance not previously evaluated 
in pairwise meta­analyses (e.g., IA v. STAN). Our systematic 
review adopted a pragmatic approach to report on all relevant 
endpoints, as reported by the authors, to synthesize the most 
comprehensive evidence on the topic that could directly apply to 
clinical practice. We assessed the risk of bias using a standard 
tool and took into account any quality improvement measures to 
improve the validity of each trial, given the complexity of the 
evaluated interventions and the chance of methodological het­
erogeneity. To reduce the risk of inconsistency in our network, 
we eliminated methods of surveillance evaluated by a single trial 
(cCTG and CTG­STAN) from the primary analysis and performed 
supplementary analyses to assess the true effect of these meth­
ods. We examined for inconsistency using the node­split 
approach and conducted a meta­regression, which found that 
the detected inconsistency could be explained by whether preg­
nancy status was high or low risk. 
All currently available methods of intrapartum fetal surveil­
lance assume that detecting subtle changes and variability in the 
fetal heart rate could identify fetuses at risk of intrapartum 
asphyxia, prompting further interventions.58 Simultaneously, 
fetal surveillance aims to identify those fetuses coping well with 
labour, regardless of the subtle changes in the fetal heart rate, to 
avoid unnecessary interventions, reassure mothers and their 
health care providers.58 Introducing IA into practice helped to 
improve the detection of acutely compromised fetuses after seri­
ous events such as placental abruption, thus reducing associated 
adverse outcomes.59 However, its accuracy to detect subacute 
hypoxia and chronic intrapartum insult remains debatable.3 Our 
Table 2: Summary of the calculated surface under the cumulative ranking curve (SUCRA) and mean rank for types of 
intrapartum fetal surveillance across maternal and neonatal outcomes* 
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100.0 1.0 26.3 4.7 33.5 4.3 N/A N/A 57.7 3.1 N/A N/A 64.7 2.8 17.8 5.1
Neonatal outcomes
Acidemia 51.8 4.4 38.9 5.3 15.5 6.9 63.7 3.5 71.2 3.0 35.5 5.5 76.2 2.7 47.2 4.7
Admission to 
NICU
42.1 5.1 38.3 5.3 49.3 4.6 37.0 5.4 75.7 2.7 78.3 2.5 10.5 7.3 68.9 3.2
Apgar < 7 at 
5th minute
75.9 2.7 26.3 6.2 64.4 3.5 13.9 7.0 39.2 5.3 52.4 4.3 79.4 2.4 48.4 4.6
Perinatal 
death
44.8 4.3 46.8 4.2 69.1 2.9 N/A N/A 36.0 4.8 80.0 2.2 32.1 5.1 41.2 4.5
Note: cCTG­FBS = computer­aided cardiotocography with fetal scalp blood pH sampling, CTG = cardiotocography, CTG­FBS = cardiotocography with fetal scalp blood pH sampling, 
CTG­lactate = cardiotocography with fetal scalp blood lactate, EmCD = emergency cesarean delivery, FPO­CTG = cardiotocography with fetal pulse oximetry, FPO­CTG­FBS = 
cardiotocography with fetal pulse oximetry and fetal blood pH sampling, IA = intermittent auscultation, N/A = no available evidence, NICU = neonatal intensive care unit, STAN­CTG­
FBS = cardiotocography with fetal heart electrocardiogram and fetal scalp blood pH sampling.
*The calculated SUCRA for all adverse outcomes expresses the lowest likelihood of developing adverse maternal and neonatal outcomes.
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analysis suggests that all additional methods introduced to 
improve the accuracy of electronic fetal heart monitoring (CTG, 
FBS, FPO, STAN and cCTG) have failed to reduce the risk of 
adverse neonatal or maternal outcomes beyond what IA 
achieved 50 years ago, and this may have contributed to the 
increased incidence of unnecessary emergency cesarean deliver­
ies. As such, the benefit of these newer surveillance methods is 
questionable, especially in view of the consistent rise in the rate 
of cesarean deliveries worldwide. The increasing incidence of 
cesarean deliveries is particularly notable in high­income coun­
tries where advanced fetal surveillance methods are readily 
available. The suboptimal performance of newer fetal surveil­
lance methods could be mediated by a higher false­positive 
detection rate or human errors in interpreting their outputs, 
driven by operator incompetence or increased interface com­
plexity. Clearly, the rising rate of cesarean deliveries is multifac­
torial60 and cannot be linked solely to poorly performing intra­
partum fetal surveillance methods. More specifically, our 
findings suggest that these technologies failed to meet their 
objective of reducing unnecessary interventions in labour.
Most included trials failed to report on key long­term neona­
tal outcomes, such as cerebral palsy, neonatal seizures and 
hypoxic–ischemic encephalopathy. Instead, most reported on 
short­term, readily recorded outcomes, such as neonatal 
acidemia and Apgar scores, all of which have a modest correla­
tion with long­term child development.61 Similarly, there was 
poor reporting on important long­term maternal outcomes fol­
lowing cesarean deliveries and instrumental deliveries, such as 
subsequent placenta accreta and anal sphincter injuries.62 Those 
long­term outcomes should be considered in future trials and 
their follow­ups, especially given the contrast between random­
ized and observational evidence on the effect of adopting newer 
fetal surveillance methods in practice.4
Given the inconsistency in evidence on the use of FPO and 
STAN compared with CTG­FBS, large, randomized trials are 
needed to determine their effectiveness in both high­ and low­
risk pregnancies when implemented in routine practice, espe­
cially given the potential high costs (e.g., hardware, software and 
staff training). Novel study designs such as multiarm, multistage 
comparison and cluster randomization trials may be better 
suited to evaluate the efficacy and effectiveness of fetal surveil­
lance in everyday clinical settings. Specifically, these trials 
should aim to evaluate the preferential use of IA and CTG in low­ 
v. high­risk pregnant people as well as the effectiveness of differ­
ent fetal surveillance algorithms across different health care set­
tings (e.g high­ v. low­income countries).
Developing and evaluating new fetal surveillance methods is 






















Figure 4: The ranking probability of types of intrapartum fetal surveillance to reduce all emergency cesarean deliveries when used in labour. The graph 
depicts the probability of each type to be ranked the highest in reducing the incidence of all emergency cesarean deliveries in labour. IA was consis­
tently ranked first, followed by STAN­CTG­FBS and CTG­FBS. Note: cCTG = computer­aided cardiotocography, cCTG­FBS = computer­aided cardioto­
cography with fetal scalp blood pH sampling, CTG = cardiotocography, CTG­FBS = cardiotocography with fetal scalp blood pH sampling, CTG­lactate = 
cardiotocography with fetal scalp blood lactate, FPO­CTG = cardiotocography with fetal pulse oximetry, FPO­CTG­FBS = cardiotocography with fetal 
pulse oximetry and fetal blood pH sampling, IA = intermittent auscultation, STAN­CTG = cardiotocography with fetal heart electrocardiogram, STAN­
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the increased safety requirements in clinical research. Given the 
modest improvement in neonatal and maternal outcomes over 
the last 50 years, boosting collaboration among researchers, 
funders, industry, policymakers and lay consumers is required to 
tackle this important health issue.63 The rapid improvement in 
communication technology could facilitate this objective and 
foster transcountry collaborations to aid joint research efforts 
and data sharing. Our meta­analysis makes the case for serious 
investment in the development and evaluation of novel intrapar­
tum surveillance technologies to make birth a safer process for 
patients and their offspring.
Limitations
Several of the trials included in our meta­analysis were rela­
tively old. Their quality differs compared with newer trials, 
especially for the elements of randomization, assignment con­
cealment and outcome assessment. This was particularly rele­
vant to trials comparing IA and CTG.33–35,37,40–43,47,52,57 Limited 
reporting on attrition, and the use of intention­to­treat analysis 
were provided in some trials, particularly those before 2000. We 
included these trials to minimize research waste, but also to 
highlight the elements of suboptimal design. Furthermore, we 
assessed their risk of bias to offer a comprehensive overview of 
changes in fetal surveillance over time. Several older trials 
included participants with different pregnancy status (high v. 
low risk) using different selection criteria. This could have an 
impact on effect sizes, though we did not detect a statistically 
significant effect in our meta­regression. A number of trials 
adopted different criteria for interpreting CTGs and fetal well­
being, which might bias the findings. However, none of the 
evaluated criteria seemed to offer better accuracy for detecting 
fetal compromise in labour.64 The definition of neonatal acide­
mia has evolved over the years, which resulted in variation 
across trials. We were unable to accommodate several poten­
tial effect modifiers, such as progress in labour, induction of 
labour, suspected fetal growth restriction, use of oxytocin aug­
mentation, operator experience and deviation from the trial’s 
protocol. Although some of these elements could be adjusted 
for in an individual patient data meta­analysis, several factors 
are difficult to measure in practice, such as severity of sepsis in 
labour and degree of fetal growth restriction. Lastly, most of 
the included trials were underpowered to detect rare adverse 
neonatal outcomes and were potentially affected by the 
 Hawthorne effect, limiting their generalizability. Our compre­
hensive analysis therefore offers a pragmatic approach that 
synthesizes the best quality evidence available to­date and 
guides future research efforts to address these limitations.
Conclusion
Compared with other types of fetal surveillance, intermittent 
auscultation seems to reduce emergency cesarean deliveries in 
labour without increasing adverse neonatal and maternal out­
comes. New fetal surveillance methods did not improve neonatal 
outcomes or reduce unnecessary maternal interventions. Further 
evidence is needed to evaluate the effects of fetal pulse oximetry 
and fetal heart electrocardiography in labour.
References
 1. Jibodu OA, Arulkumaran S. Intrapartum fetal surveillance. Curr Opin Obstet 
Gynecol 2000;12:123­7.
 2. Intrapartum care for healthy women and babies. London (UK): The National 
Institute for Health and Care Excellence; 2014; Available: https://www.nice.
org.uk/guidance/cg190 (accessed 2021 Jan. 1). 
 3. Steer PJ. Has electronic fetal heart rate monitoring made a difference? Semin 
Fetal Neonat Med  2008;13:2­7.
 4. Olofsson P, Ayres de Campos D, Kessler J, et al. A critical appraisal of the evidence 
for using cardiotocography plus ECG ST interval analysis for fetal surveillance in 
labor. Part II: the meta analyses. Acta Obstet Gynecol Scand 2014;93:571­86.
 5. Carbonne B, Pons K, Maisonneuve E. Foetal scalp blood sampling during labour for 
pH and lactate measurements. Best Pract Res Clin Obstet Gynaecol 2016;30:62­7.
 6. INFANT Collaborative Group. Computerised interpretation of fetal heart rate 
during labour (INFANT): a randomised controlled trial. Lancet 2017;389:1719­29.
 7. Molina G, Weiser TG, Lipsitz SR, et al. Relationship between cesarean delivery 
rate and maternal and neonatal mortality. JAMA 2015;314:2263­70.
 8. Blencowe H, Cousens S, Jassir FB, et al. National, regional, and worldwide esti­
mates of stillbirth rates in 2015, with trends from 2000: a systematic analysis. 
Lancet Glob Health 2016;4:e98­108.
 9. Thacker SB, Stroup D, Chang M. Continuous electronic heart rate monitoring 
for fetal assessment during labor. Cochrane Database Syst Rev 2001;(2): CD000063.
10. Alfirevic Z, Gyte GML, Cuthbert A,  et al. Continuous cardiotocography (CTG) as 
a form of electronic fetal monitoring (EFM) for fetal assessment during labour. 
Cochrane Database Syst Rev 2017;(2):CD006066.
11. East CE, Begg L, Colditz PB, et al. Fetal pulse oximetry for fetal assessment in 
labour. Cochrane Database Syst Rev 2014;(10):CD004075.
12. Martis R, Emilia O, Nurdiati DS, et al. Intermittent auscultation (IA) of 
fetal heart rate in labour for fetal well being. Cochrane Database Syst Rev 
2017;(2): CD008680.
13. Saccone G, Schuit E, Am­Wåhlin I, et al. Electrocardiogram ST analysis during 
labor: a systematic review and meta­analysis of randomized controlled trials. 
Obstet Gynecol 2016;127:127­35.
14. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for 
reporting of systematic reviews incorporating network meta­analyses of health 
care interventions: checklist and explanations. Ann Intern Med 2015;162:777­84.
15. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool 
for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
16. White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in net­
work meta analysis: model estimation using multivariate meta regression. Res 
Synth Methods 2012;3:111­25.
17. White IR. Network meta­analysis. Stata J 2015;15:951­85. 
18. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summa­
ries for presenting results from multiple­treatment meta­analysis: an overview 
and tutorial. J Clin Epidemiol 2011;64:163­71.
19. Chaimani A, Higgins JPT, Mavridis D, et al. Graphical tools for network meta­
analysis in STATA. PLoS One 2013;8:e76654.
20. Higgins JPT, Jackson D, Barrett JK, et al. Consistency and inconsistency in net­
work meta analysis: concepts and models for multiarm studies. Res Synth 
Methods 2012;3:98­110.
21. Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment 
comparison meta analysis. Stat Med 2010;29:932­44.
22. Veroniki AA, Vasiliadis HS, Higgins JPT, et al. Evaluation of inconsistency in 
networks of interventions. Int J Epidemiol 2013;42:332­45.
23. Dias S, Ades AE, Welton NJ, et al. Network meta-analysis for decision-making. 
Hoboken (NJ): John Wiley & Sons; 2018.
24. White IR. Multivariate random­effects meta­regression: updates to mvmeta. 
Stata J 2011;11:255­70.
25. Amer­Wåhlin I, Hellsten C, Norén H, et al. Cardiotocography only versus car­
diotocography plus ST analysis of fetal electrocardiogram for intrapartum fetal 
monitoring: a Swedish randomised controlled trial. Lancet 2001; 358:534­8. 
26. Belfort MA, Saade GR, Thom E, et al. A randomized trial of intrapartum fetal 
ECG ST­segment analysis. N Engl J Med 2015;373:632­41.
27. Bloom SL, Spong CY, Thom E, et al. Fetal pulse oximetry and cesarean delivery. 
N Engl J Med 2006;355:2195­202.
28. INFANT Collaborative Group. Computerised interpretation of fetal heart rate 
during labour (INFANT): a randomised controlled trial. Lancet 2017; 389: 1719­29.
29. Caliskan E, Cakiroglu Y, Corakci A, et al. Reduction in caesarean delivery with 
fetal heart rate monitoring and intermittent pulse oximetry after induction of 
labour with misoprostol. J Matern Fetal Neonatal Med 2009;22:445­51.
30. East CE, Brennecke SP, King JF, et al., FOREMOST Study Group. The effect of 
intrapartum fetal pulse oximetry, in the presence of a nonreassuring fetal 
heart rate pattern, on operative delivery rates: a multicenter, randomized, 
controlled trial (the FOREMOST trial). Am J Obstet Gynecol 2006;194:606­e1­16.
RESEARCH
 CMAJ  |  APRIL 6, 2021  |  VOLUME 193  |  ISSUE 14 E477
31. East C, Davey MA, Kamlin O, et al. Randomised trial of fetal scalp blood sam­
pling for lactate measurement: The Flamingo trial. BJOG 2016;123.
32. Garite TJ, Dildy GA, McNamara H, et al. A multicenter controlled trial of fetal 
pulse oximetry in the intrapartum management of nonreassuring fetal heart 
rate patterns. Am J Obstet Gynecol 2000;183:1049­58.
33. Haverkamp AD, Thompson HE, McFee JG, et al. The evaluation of continuous 
fetal heart rate monitoring in high­risk pregnancy. Am J Obstet Gynecol 1976; 
125:310­20.
34. Haverkamp AD, Orleans M, Langendoerfer S, et al. A controlled trial of the differen­
tial effects of intrapartum fetal monitoring. Am J Obstet Gynecol 1979;134:399­412.
35. Herbst A, Ingemarsson I. Intermittent versus continuous electronic monitoring 
in labour: a randomised study. Br J Obstet Gynaecol 1994;101:663­8.
36. Ignatov PN, Lutomski JE. Quantitative cardiotocography to improve fetal 
assessment during labor: a preliminary randomized controlled trial. Eur J Obstet 
Gynecol Reprod Biol 2016;205:91­7.
37. Kelso IM, Parsons RJ, Lawrence GF, et al. An assessment of continuous fetal heart 
rate monitoring in labor: a randomized trial. Am J Obstet Gynecol 1978;131:526­32.
38. Klauser CK, Christensen EE, Chauhan SP, et al. Use of fetal pulse oximetry 
among high­risk women in labor: a randomized clinical trial. Am J Obstet Gyne-
col 2005;192:1810­7.
39. Kühnert M, Schmidt S. Intrapartum management of nonreassuring fetal heart rate 
patterns: a randomized controlled trial of fetal pulse oximetry. Am J Obstet Gynecol 
2004;192:1989­95.
40. MacDonald D, Grant A, Sheridan­Pereira M, et al. The Dublin randomized con­
trolled trial of intrapartum fetal heart rate monitoring. Am J Obstet Gynecol 
1985;152:524­39.
41. Madaan M, Trivedi SS. Intrapartum electronic fetal monitoring vs. intermittent 
auscultation in postcesarean pregnancies. Int J Gynaecol Obstet 2006;94:123­5.
42. Mdoe PF, Ersdal HL, Mduma E, et al. Randomized controlled trial of continuous 
Doppler versus intermittent fetoscope fetal heart rate monitoring in a low 
resource setting. Int J Gynaecol Obstet 2018;143:344­50.
43. Neldam S, Osler M, Hansen PK, et al. Intrapartum fetal heart rate monitoring in 
a combined low­and high­risk population: a controlled clinical trial. Eur J Obstet 
Gynecol Reprod Biol 1986;23:1­11.
44. Nunes I, Ayres­de­Campos D, Ugwumadu A, et al. Central fetal monitoring with 
and without computer analysis. Obstet Gynecol 2017;129:83­90.
45. Ojala K, Vääräsmäki M, Mäkikallio K, et al. A comparison of intrapartum auto­
mated fetal electrocardiography and conventional cardiotocography—a ran­
domised controlled study. BJOG 2006;113:419­23.
46. Puertas A, Góngora J, Valverde M, et al. Cardiotocography alone vs. cardioto­
cography with ST segment analysis for intrapartum fetal monitoring in women 
with late­term pregnancy. A randomized controlled trial. Eur J Obstet Gynecol 
Reprod Biol 2019;234:213­7.
47. Renou P, Chang A, Anderson I, et al. Controlled trial of fetal intensive care. 
Am J Obstet Gynecol 1976;126:470­6.
48. Strachan BK, van Wijngaarden WJ, Sahota D, et al., FECG Study Group. Car­
diotocography only versus cardiotocography plus PR­interval analysis in intra­
partum surveillance: a randomised, multicentre trial. Lancet 2000;355:456­9.
49. Valverde M, Puertas AM, Lopez­Gallego MF, et al. Effectiveness of pulse oxime­
try versus fetal electrocardiography for the intrapartum evaluation of nonreas­
suring fetal heart rate. Eur J Obstet Gynecol Reprod Biol 2011;159:333­7.
50. van Wijngaarden WJ, Sahota DS, James DK, et al. Improved intrapartum surveil­
lance with PR interval analysis of the fetal electrocardiogram: a randomized trial 
showing a reduction in fetal blood sampling. Am J Obstet Gynecol 1996;174:1295­9.
51. Vayssière C, David E, Meyer N, et al. A French randomized controlled trial of ST­
segment analysis in a population with abnormal cardiotocograms during 
labor. Am J Obstet Gynecol  2007;197:299­e1.
52. Vintzileos AM, Antsaklis A, Varvarigos I, et al. A randomized trial of intrapartum 
electronic fetal heart rate monitoring versus intermittent auscultation. Obstet 
Gynecol 1993;81:899­907.
53. Westerhuis ME, Moons KG, van Beek E, et al. A randomised clinical trial on car­
diotocography plus fetal blood sampling versus cardiotocography plus ST­
analysis of the fetal electrocardiogram (STAN®) for intrapartum monitoring. 
BMC Pregnancy Childbirth 2007;7:1­8.
54. Westgate J, Harris M, Curnow JS, et al. Randomised trial of cardiotocography alone 
or with ST waveform analysis for intrapartum monitoring. Lancet 1992;340:194­8.
55. Westgren M, Kruger K, Ek S, et al. Lactate compared with pH analysis at fetal 
scalp blood sampling: a prospective randomised study. BJOG 1998;105:29­33.
56. Wiberg­Itzel E, Lipponer C, Norman M, et al. Determination of pH or lactate in 
fetal scalp blood in management of intrapartum fetal distress: randomised 
controlled multicentre trial. BMJ 2008;336:1284­7.
57. Wood C, Renou P, Oats J, et al. A controlled trial of fetal heart rate monitoring 
in a low­risk obstetric population. Am J Obstet Gynecol 1981;141:527­34.
58. Devoe LD. Future perspectives in intrapartum fetal surveillance. Best Pract Res 
Clin Obstet Gynaecol 2016;30:98­106.
59. Goddard R. Electronic fetal monitoring: is not necessary for low risk labours. 
BMJ 2001;322:1436­7.
60. Betrán AP, Torloni MR, Zhang J­J, et al. WHO statement on caesarean section 
rates. BJOG  2016;123:667­70.
61. Sabol BA, Caughey AB. Acidaemia in neonates with a 5­minute Apgar score of 7 
or greater — What are the outcomes? Am J Obstet Gynecol 2016;215:486.e1­6.
62. Grivell RM, Dodd JM. Short­and long­term outcomes after cesarean section. 
Expert Rev of Obstet Gynecol 2011;6:205­15.
63. Adam J. The future of fetal monitoring. Rev Obstet Gynecol 2012;5:e132­6.
64. Garabedian C, Butruille L, Drumez E, et al. Inter­observer reliability of 4 fetal 
heart rate classifications. J Gynecol Obstet Hum Reprod 2017;46:131­5.
Competing interests: None declared.
This article has been peer reviewed.
Affiliations: Warwick Medical School (Al Wattar, 
Honess, Bunnewell, Quenby), University of 
Warwick, Coventry, UK; Reproductive Medi­
cine Unit (Al Wattar), University College Lon­
don Hospitals, London, UK; Population Health 
Sciences (Welton), Bristol Medical School, Uni­
versity of Bristol, Bristol, UK; University Hospi­
tal of Coventry and Warwickshire (Quenby), 
Coventry, UK; Department of Preventive Medi­
cine and Public Health (Khan), University of 
Granada, Granada, Spain; Clinical Biostatistics 
Unit, Ramon y Cajal Hospital (IRYCIS) and 
CIBER Epidemiology and Public Health (Khan, 
Zamora), Madrid, Spain; CIBER of Epidemiol­
ogy and Public Health (CIBERESP) (Zamora), 
Madrid, Spain; WHO Collaborating Centre for 
Global Women’s Health, Institute of Metab­
olism and Systems Research (Thangaratinam), 
University of Birmingham; Birmingham Wom­
en’s and Children’s NHS Foundation Trust 
(Thangaratinam), Birmingham, UK
Contributors: Bassel Al Wattar conceived and 
designed the study. Bassel Al Wattar, Emma 
Honess and Sarah Bunnewell acquired the 
data. All authors contributed to the analysis 
and interpretation of data. Bassel Al Wattar 
drafted the initial manuscript, which all 
authors critically revised for important intel­
lectual content. All authors gave final approval 
of the version to be published and agreed to 
be accountable for all aspects of the work.
Content licence: This is an Open Access article 
distributed in accordance with the terms of the 
Creative Commons Attribution (CC BY­NC­ND 
4.0) licence, which permits use, distribution 
and reproduction in any medium, provided 
that the original publication is properly cited, 
the use is noncommercial (i.e., research or edu­
cational use), and no modifications or adapta­
tions are made. See: https://creativecommons.
org/licenses/by­nc­nd/4.0/
Funding: Bassel Al Wattar holds a personal 
Academic Clinical Lectureship from the UK 
National Health Institute of Research. Khalid 
Khan is a Distinguished Investigator funded by 
the Beatriz Galindo (senior modality) Program 
Grant given to the University of Granada by 
the Ministry of Science, Innovation, and Uni­
versities of the Spanish Government.
Copyright: This is an Open Access article dis­
tributed in accordance with the terms of the 
Creative Commons Attribution (CC BY 4.0) 
license, which permits others to distribute, 
remix, adapt and build upon this work, for 
commercial use, provided the original work is 
properly cited. See: http://creativecommons.
org/licenses/by/4.0/. 
Data sharing: All data included in this study is 
available to other researchers for use in scien­
tific research. Requests should be made to the 
corresponding authors stating the purpose 
and type of data required.
Accepted: Jan. 18, 2021 
Correspondence to: Bassel Al Wattar, dr.
basselwa@gmail.com
